Compare FOA & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FOA | CMPX |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.7M | 752.4M |
| IPO Year | N/A | N/A |
| Metric | FOA | CMPX |
|---|---|---|
| Price | $22.81 | $5.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $29.75 | $13.44 |
| AVG Volume (30 Days) | 120.9K | ★ 2.1M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $318,296,000.00 | N/A |
| Revenue This Year | $29.44 | N/A |
| Revenue Next Year | $14.30 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.58 | $1.33 |
| 52 Week High | $32.40 | $5.86 |
| Indicator | FOA | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 45.44 | 51.71 |
| Support Level | $22.20 | $4.83 |
| Resistance Level | $23.35 | $5.27 |
| Average True Range (ATR) | 0.83 | 0.30 |
| MACD | -0.07 | -0.07 |
| Stochastic Oscillator | 25.64 | 27.57 |
Finance of America Companies Inc is a financial services holding company that, through its operating subsidiaries, is a modern retirement solutions platform that provides customers with access to a range of retirement offerings centered on the home. In addition, FoA offers capital markets and portfolio management capabilities to optimize the distribution of its originated loans to investors. It operates through two segments: Retirement Solutions and Portfolio Management. It generates the majority of its revenue from Retirement Solutions.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.